- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Flow Cytometry - Articles and news items
Flow cytometry is an extremely useful technique for the rapid analysis of many cell types. Here, the applications of this technique for the monitoring and optimisation of microbial recombinant protein production processes are discussed…
The last 10 years in biomedical research marks the period of deepening our understanding of the human genome. In the context of cancer research, The Cancer Genome Atlas (TCGA) and related international genomics efforts have now revealed the full complexity of genomic aberrations in human cancers that are postulated to contribute to the aspects of cancer pathophysiology. It is plausible that an ensemble of the numerous aberrations in each individual tumour collaborate at various strengths to deregulate master signalling pathways of cells, thereby enabling the established cancer ‘hallmarks’.
Technological and sociological advances in HTS: evolution and revolution?
Flow cytometry as a drug screening platform
Show Preview: High-Content Analysis 2014
Improving the quantitation of live antigens used to produce rabbit generated serotype specific antiserum
This is the first paper in our continuing series on Rapid Microbiological Methods (RMM) that will appear in European Pharmaceutical Review during 2013. Flow cytometry represents one of a variety of viability-based RMM technologies that are currently available to the pharmaceutical industry. In flow cytometry, individual particles are counted as they pass through a laser beam in a very narrow flow cell.
Flow Cytometry, Issue 4 2012 / 3 September 2012 / Jonni Moore, Professor of Pathology and Laboratory Medicine, Director, Clinical Flow Cytometry, Hospital of University of Pennsylvania, Director, Abramson Cancer Center Flow Cytometry and Cell Sorting Shared Resource – Perelman School of Medicine of the University of Pennsylvania and Pascal Yvon, CEO, CytoVas
Technologies for single cell analysis have recently become prominent in the emerging life science sectors. The last few decades have seen an explosion in advancements in cytometric technologies encompassing instrumentation, probes and data analysis. In particular, flow cytometry has become a well-established and routine method in clinical laboratories. Recent developments have placed high dimensional flow cytometry at the forefront of new applications critical for the pharmaceutical sector and clinical laboratories. The integration of systems biology concepts into biomedical studies has resulted in trans – formative advancements in both the amount and type of information that can be gained to help understand the basis of biocomplexity in health and disease. All aspects of a biological process from biochemical, genetic and cellular to clinical and environmental can be integrated using computational models to derive unique signatures from vast amounts of data. The changes in these signatures, often unique to the individual, can serve to define patho – physiological conditions…
Flow Cytometry, Issue 2 2012 / 26 April 2012 / J. Paul Robinson, Purdue University Cytometry Laboratories & Weldon School of Biomedical Engineering, Purdue University; Bernd Bodenmiller, Group leader, Institute of Molecular Life Sciences, University of Zurich; Valery Patsekin and Bartek Rajwa, Purdue University Cytometry Laboratories, Purdue University; and V. J. Davisson, Medicinal Chemistry & Molecular Pharmacology, Purdue University
Flow cytometry is the technology that has the most impact on single-cell analysis. Over the past 40 years, it has arguably been the single most important research technique in the fields of basic and applied immunology. Flow cytometry excels in quantitative evaluation of receptor expression, separation of functionally defined cell populations and monitoring of cellular differentiation. For the clinical sciences, flow cytometry has been a key tool for diagnostics whereby aberrant populations are identified, classified and quantified, and in situations such as minimal residual disease, is capable of identifying rare cells indicative of dysplasia.
Despite the importance of its applications, flow cytometry is often seen as an aging technique without new exciting opportunities. The reality could not be further from the truth. The systems biology approach breathes new life into this unique technology. The new challenges of complex analysis of networks and pathways are a natural fit for modern multifactorial flow cytometry.
At the dawn of modern immunology, Len Herzenberg at Stanford University demonstrated the power of this high-tech tool in the early 1970s and it was soon the select tool for immunologists1. The advantage of flow cytometry was clear to most.
Biomarker research has become one of the integral aspects in drug discovery and development. It is broadly utilised to confirm drug mechanism of action (MOA), explore PK/PD correlation, support dose selection and predict response to treatment. Therefore, biomarker data provide valuable information to guide clinical decisions, support drug filings with regulatory agencies and ultimately increase the market value of the drug.
Flow cytometry is a powerful technology for the analysis of multiple biological parameters of individual cells within heterogeneous cell populations. It is widely being used in biomarker research to monitor development and differentiation of cell populations, evaluate target engagement and biomarker expression on/in the cells and assess cell functions and signalling events.
Flow cytometry can be used to advance our understanding of diseases in multiple ways. Drug effects and dosages can be ascertained in vitro, along with patient selection based on mutations and antigen profiles. Within the Diagnostic Biomarkers group of Translational Research at Pfizer, we are utilising flow cytometry in conjunction with other diagnostic tools to assist in gaining a clearer understanding of drug target biology and to identify patients that would benefit most from a specified drug regimen.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics